Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency

Clinical Evaluation of the Safety and Efficacy of the InMode RF Pro System With the Morpheus8 Applicator (With the 24 Pin Tip) for the Treatment of Primary Focal Hyperhidrosis of the Axillae Using Fractional RF Technology

The InMode radio frequency Pro System with the Morpheus8 Applicator is a computerized system generating radio frequency energy, based on the underlying technology of Fractional RF. The Morpheus8 Applicator and 24 pin tip is used for the treatment of primary hyperhidrosis of the axillae

Study Overview

• Status: Recruiting
• Conditions: Hyperhidrosis Primary Focal Axilla
• Intervention / Treatment: Device: Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.

Detailed Description

Study subjects will be consecutively screened and enrolled into the study. The study will consist of an active group that will receive 2 treatments with the InMode radio frequency Pro System with the Morpheus8 Applicator (with the 24 pin tip) and a sham group that will receive 2 sham treatments with the same InMode radio frequency Pro System and Morpheus8 Applicator (with a sham 24 pin tip). Treatment will be performed in a preheated controlled environment (T°≥22°C). Follow up visits will occur at 1 month, 3 months, and 6 months post treatment

• Study Type: Interventional
• Enrollment (Estimated): 70
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Meital Matalon, MS; Phone Number: 949 258-8870; Email: meital.matalon@inmodemd.com
• Study Contact Backup: Name: Maria Shusterman, RN; Phone Number: 9492396522; Email: maria.shusterman@inmodemd.com

Study Locations

• Israel
  • Haifa, Israel
    • Not yet recruiting
    • Rambam Medical Center
    • Contact: Rinat Lasker; Phone Number: +972 4 777 1738; Email: r_lasker@rambam.health.gov.il
• United States
  • New York
    • New York, New York, United States, 11746
      • Active, not recruiting
      • Skinfluence
  • Tennessee
    • Knoxville, Tennessee, United States, 37922
      • Recruiting
      • Southeastern Dermatology
      • Contact: Prianca Patel; Phone Number: 865-474-8800; Email: ppatel@drdoppelt.com
  • Texas
    • Dallas, Texas, United States, 75231
      • Recruiting
      • Dallas Plastic Surgery Institute
      • Contact: :Rachelle Winkle, RN; Phone Number: 214-821-9114; Email: rachelle.winkle@dpsi.org
      • Principal Investigator: Rod Rohrich, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Subject is 18 years of age or older at the time of consent.

• Subject reports a quality-of-life rating of 3 or 4 on the Hyperhidrosis Disease Severity Scale (HDSS).
• Subject has primary focal axillary hyperhidrosis evidenced by at least 6 months of visible, detectable, focal, exaggerated sweating without any apparent explanation and at least two of the following:
• Bilateral and relatively symmetric
• Impairs daily activities
• Frequency of at least one episode per week
• Age of onset less than 25 years old
• Positive family history
• Cessation of focal sweating during sleep
• Subject is willing and able to comply with protocol requirements and all study visits
• Willing to have de-identified images of the treated areas taken for possible use in publications and presentations.
• Subject understands the study and has provided written informed consent

Exclusion Criteria:

Subject has secondary hyperhidrosis due to medications, infections, malignancy or endocrinopathy.

• Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
• Severe concurrent conditions such as cardiac disorders epilepsy, uncontrolled hypertension, and liver or kidney diseases.
• Any active skin condition in the treatment area, such as sores, psoriasis, eczema and rash.
• Swollen axillary lymph nodes.
• History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
• Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
• History of bleeding coagulopathies or use of anticoagulants in the last 10 days.
• Prior endoscopic thoracic sympathectomy, liposuction or other surgery for hyperhidrosis in the treated area. Injection of botulinum toxin in the treated area within one year
• Use of Isotretinoin (Accutane®) within 6 months prior to study
• Oral anticholinergic medication use (e.g., Robinul) or cholinomimetic medication use within the last 4 weeks or planned use during the study's follow up phase.
• Currently participating in or recently participated in another clinical trial (within the last 30 days).
• History of or current neurologic deficit in the treatment limb.
• Known resistance to or history of difficulty with local anesthesia (lidocaine with epinephrine).
• Current or history of cancer, including skin cancer, or premalignant moles.
• Injury in the treatment area or any other condition that, in the opinion of the investigator, might make treatment unsafe.
• Subject has a pacemaker, defibrillator or other electronic implant anywhere in the body.
• Permanent implant in the treated area such as metal plates, screws and metal piercing or silicon.
• Females who are pregnant or nursing
• Female subjects of childbearing potential not willing to use an acceptable form of contraception for the duration of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active group; Active group that will receive 2 treatments with the InMode RF Pro System with the Morpheus8 Applicator (with the 24 pin tip)	Device: Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.; After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment
Sham Comparator: Sham group; Sham group that will receive 2 sham treatments with the same InMode RF Pro System and Morpheus8 Applicator (with a sham 24 pin tip).	Device: Morpheus8 Applicator (with the 24 pin tip) in the treatment of primary axillary hyperhidrosis.; After subjects meet the eligibility criteria, they will be randomized with a 1:1 ratio to one of two treatment groups: Active or Sham. Subjects will receive two active or sham treatments, one month apart, with the InMode RF Pro System with the Morpheus8 Applicator and 24 pins tip and will return for three follow up visits: 4 weeks 12 weeks and 24 weeks post the second treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
A statistically significant difference in the percent of responders defined as subjects reporting a Hyperhidrosis Disease Severity Scale (HDSS) score of 1 or 2 at the 4-week	A statistically significant difference in the percent of responders, defined as subjects reporting a Hyperhidrosis Disease Severity Scale (HDSS) score of 1 or 2 at the 4-week follow-up visit, in the treatment group compared to the sham group	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of subjects with a perspiration intensity of 0-2 on the Minor's starch-iodine test Intensity	Percent of subjects with a perspiration intensity of 0-2 on the Minor's starch-iodine test Intensity Visual Scale at the 4-week follow-up visit in the treatment group compared to the sham group	4 weeks
Percent of responders, defined as subjects reporting a Hyperhidrosis Disease Severity Scale (HDSS) score of 1 or 2	Percent of responders, defined as subjects reporting a Hyperhidrosis Disease Severity Scale (HDSS) score of 1 or 2 at the 12-week follow-up visit in the treatment group compared to the sham group.	12 weeks
Percent of subjects who achieved a 2-point or greater decline in the Hyperhidrosis Disease Severity Scale.	Percent of subjects who achieved a 2-point or greater decline in Hyperhidrosis Disease Severity Scale. from baseline at 4 weeks follow-up in the treatment group compared to the sham group	4 weeks

Collaborators and Investigators

• Sponsor: InMode MD Ltd.
• Investigators: Principal Investigator: Rodney J Rohrich, MD

Study record dates

Study Major Dates

• Study Start (Actual): March 9, 2023
• Primary Completion (Estimated): April 1, 2025
• Study Completion (Estimated): April 1, 2026

Study Registration Dates

• First Submitted: May 5, 2023
• First Submitted That Met QC Criteria: May 5, 2023
• First Posted (Actual): May 16, 2023

Study Record Updates

• Last Update Posted (Actual): January 12, 2024
• Last Update Submitted That Met QC Criteria: January 11, 2024
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: hyperhidrosis
• Additional Relevant MeSH Terms: Sweat Gland Diseases; Skin Diseases; Hyperhidrosis
• Other Study ID Numbers: DO611232A

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No